AAVantgarde Completes Enrollment in LUCE-1 Phase 1/2 Clinical Trial of AAVB-081 for Usher Syndrome Type B-associated Retinitis Pigmentosa January 15, 2026
AGC Biologics to Manufacture AAVantgarde’s Dual-Vector Gene Therapies for Inherited Retinal Disorders November 24, 2025
Italian biotech AAVantgarde adds $141M series B to fund retinal disease gene therapy trials November 3, 2025
